0
Signin
countryflagCA

888-969-2592

RY 156.04 -0.032% TD 79.81 -0.4615% SHOP 99.81 0.9303% CNR 158.79 0.6401% ENB 53.84 0.4478% CP 111.87 0.8019% BMO 112.71 0.7419% TRI 225.62 0.396% CNQ 50.46 2.4777% BN 67.8 1.194% ATD 76.93 -1.0674% CSU 4321.5298 0.3257% BNS 67.27 1.3102% CM 78.76 1.5603% SU 54.66 -1.1037% TRP 62.42 1.2162% NGT 70.54 0.2558% WCN 251.32 0.3153% MFC 36.65 -0.0818% BCE 47.21 0.3187%

INVO Bioscience Inc

Healthcare US INVO

0.8012USD
0.02(2.72%)

Last update at 2024-08-30T20:00:00Z

Day Range

0.780.84
LowHigh

52 Week Range

0.508.60
LowHigh

Fundamentals

  • Previous Close 0.78
  • Market Cap3.43M
  • Volume171853
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.99834M
  • Revenue TTM4.25M
  • Revenue Per Share TTM1.80
  • Gross Profit TTM 0.54M
  • Diluted EPS TTM-1.45

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.88964M -6.65018M -8.34728M -2.16711M -3.07609M
Minority interest - - - - -
Net income -10.89251M -6.65494M -8.34732M -2.16754M -3.07609M
Selling general administrative 10.57M 9.02M 6065066.00M 3.13M 3.04M
Selling and marketing expenses - - - - -
Gross profit 0.49M 4.02M 0.95M 1.34M 0.40M
Reconciled depreciation 0.31M 0.17M 0.03M 0.03M 0.00519M
Ebit -10.62648M -5.21652M -5.51497M -1.81344M -2.63406M
Ebitda -10.82673M -5.37433M -5.51078M -1.78809M -2.62887M
Depreciation and amortization -0.20025M -0.15780M 0.00419M 0.03M 0.00519M
Non operating income net other - - - - -
Operating income -10.62648M -5.21652M -5.51497M -1.78809M -2.63406M
Other operating expenses 11.45M 9.38M 6.55M 3.27M 3.13M
Interest expense 0.06M 1.27M 2.84M 0.38M 0.44M
Tax provision 0.00287M 0.00476M 0.00004M 0.00043M 0.00000M
Interest income 0.00031M 0.00366M 0.00419M - -
Net interest income -0.05914M -1.26170M -2.83231M -0.37902M -0.44203M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00287M 0.00476M 0.00004M 0.00043M -
Total revenue 0.82M 4.16M 1.04M 1.48M 0.49M
Total operating expenses 11.12M 9.23M 6.46M 3.13M 3.04M
Cost of revenue 0.33M 0.15M 0.09M 0.14M 0.09M
Total other income expense net -0.26316M -1.43365M -2.83231M -0.37902M -0.44203M
Discontinued operations - - - - -
Net income from continuing ops -10.89251M -6.65494M -8.34732M -2.16754M -3.07609M
Net income applicable to common shares -10.89251M -6.65494M -8.34732M -2.16754M -3.07609M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 20.89M 4.10M 10.47M 10.95M 1.80M
Intangible assets 4.09M - 0.13M 0.09M 0.06M
Earning assets - - - - -
Other current assets 0.62M 0.19M 0.28M 0.16M 0.20M
Total liab 19.99M 5.08M 3.16M 5.20M 5.51M
Total stockholder equity 0.89M -0.97761M 7.31M 5.74M -3.71360M
Deferred long term liab - - - - -
Other current liab 3.57M 0.95M 0.58M 0.53M 0.39M
Common stock 0.00025M 0.00122M 0.00119M 0.00096M 0.02M
Capital stock 6.00M 0.00122M 0.00119M 0.00096M 0.02M
Retained earnings -57.81815M -49.78353M -38.89102M -32.23608M -23.88877M
Other liab - 0.00195M 0.00114M 2.86M 3.57M
Good will 5.88M - - - -
Other assets - - - 0.00024M -
Cash 0.23M 0.09M 5.68M 10.10M 1.24M
Cash and equivalents - - - - -
Total current liabilities 8.22M 3.41M 1.25M 2.29M 1.50M
Current deferred revenue 0.41M 0.12M 0.00590M 0.71M 0.71M
Net debt 8.45M 2.57M -3.56132M -9.32274M -0.78112M
Short term debt 1.91M 0.99M 0.22M 0.72M 0.02M
Short long term debt 1.51M 0.76M - 0.69M -
Short long term debt total 8.68M 2.66M 2.12M 0.78M 0.46M
Other stockholder equity 58.71M 48.80M 46.20M 37.98M 20.16M
Property plant equipment - 2.24M 2.54M 0.21M 0.19M
Total current assets 1.26M 0.62M 6.31M 10.54M 1.54M
Long term investments 3.09M 1.24M 1.49M 0.10M -
Net tangible assets - -0.97761M 7.18M 5.65M -3.77070M
Short term investments -2.17200M - - 0.10M -
Net receivables 0.14M 0.08M 0.05M 0.02M 0.00756M
Long term debt 1.25M - - - 0.35M
Inventory 0.26M 0.26M 0.29M 0.27M 0.10M
Accounts payable 2.33M 1.35M 0.44M 0.33M 0.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -6.00000M - - - -0.04215M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00096M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.91M 1.81M 3.53M 0.00024M 0.25M
Deferred long term asset charges - - - - -
Non current assets total 19.63M 3.48M 4.16M 0.40M 0.25M
Capital lease obligations 5.92M 1.90M 2.12M 0.08M 0.10M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.08122M -2.15351M -0.18725M -0.09808M -0.09808M
Change to liabilities 1.02M -3.45103M -0.75685M 4.07M -0.35892M
Total cashflows from investing activities -0.08122M -2.15351M -0.18725M -0.11471M -0.01940M
Net borrowings 0.80M -0.25000M 2.35M -0.22947M 0.78M
Total cash from financing activities 1.09M 3.77M 13.82M -0.22947M 0.86M
Change to operating activities 0.24M -0.10337M 0.09M -1.28032M 0.44M
Net income -10.89251M -6.65494M -8.34732M -2.16754M -3.07609M
Change in cash -5.59474M -4.41289M 8.86M 1.03M 0.19M
Begin period cash flow 5.68M 10.10M 1.24M 0.21M 0.03M
End period cash flow 0.09M 5.68M 10.10M 1.24M 0.21M
Total cash from operating activities -6.60332M -6.02991M -4.77515M 1.37M -0.65297M
Issuance of capital stock 0.29M 3.65M 11.48M 0.00000M 0.08M
Depreciation 0.31M 0.17M 0.03M 0.03M 0.00519M
Other cashflows from investing activities - - -0.00024M -0.00024M -0.00024M
Dividends paid - - - - -
Change to inventory 0.02M -0.02240M -0.16398M -0.05787M 0.02M
Change to account receivables -0.02668M -0.02877M -0.01414M 0.22M -0.13920M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.80M 0.37M 3.16M -0.11471M 0.90M
Change to netincome 2.68M 2.88M 1.76M 0.23M 2.09M
Capital expenditures 0.01M 0.45M 0.09M 0.11M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.25M -3.60597M -0.84552M 2.95M -0.04086M
Stock based compensation 2.22M 2.71M 1.76M 0.13M 2.09M
Other non cash items 0.51M 1.19M 2.59M 0.43M 0.37M
Free cash flow -6.61605M -6.48456M -4.86408M 1.26M -0.67237M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INVO
INVO Bioscience Inc		 0.02 2.72% 0.80 - - 1.11 5.72 5.16 -1.285
ABT
Abbott Laboratories		 0.51 0.45% 113.27 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 2.49 0.70% 360.42 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.39 0.44% 88.58 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.12 1.39% 81.79 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

INVO Bioscience Inc

5582 Broadcast Court, Sarasota, FL, United States, 34240

Key Executives

Name Title Year Born
Mr. Steven M. Shum CEO & Director 1971
Mr. Andrea Goren Chief Financial Officer 1967
Mr. Michael Jos. Campbell COO & VP of Bus. Devel. 1958
Dr. Kevin Doody M.D. Medical Director & Director 1959
Mr. Bojan Mitrovic Ph.D. Director of Sales US NA
Dr. Barbara Levy F.A.C.S., FACOG, M.D. Sr. VP of Global Clinical Integration NA
Mr. Chris Myer Sr. VP of Bus. Devel. of Americas NA
Mr. Robert Joseph Bowdring Jr. Treasurer & Sec. 1958
Ms. Terah Krigsvold Controller NA
Ms. Lori Marzilli-Kahler VP of Global Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.